Fresenius Medical (FMS) Fundamental Analysis: Revenue, Earnings & Valuation

5.20 / 10

Netural

Fundamental metrics score 5.2/10, indicating mixed standing. Revenue‑to‑market value and cash‑up are strong, and EPS growth is robust. However, total profit YoY growth and cash‑to‑market value lag, creating a balanced outlook.

Analysis Checks(8/10)

Revenue-MV

Value1.51

Score2/3

Weight12.95%

1M Return3.89%

Net cash flow from operating activities per share (YoY growth rate %)

Value18.04

Score2/3

Weight10.50%

1M Return3.60%

Inventory turnover ratio

Value6.94

Score2/3

Weight5.24%

1M Return1.88%

Net income-Revenue

Value-0.17

Score2/3

Weight15.85%

1M Return4.82%

Basic earnings per share (YoY growth rate %)

Value83.61

Score3/3

Weight20.29%

1M Return6.64%

Total profit (YoY growth rate %)

Value43.08

Score1/3

Weight5.83%

1M Return1.97%

Net cash flow from operating activities (YoY growth rate %)

Value12.36

Score2/3

Weight11.20%

1M Return3.84%

Cash-UP

Value0.29

Score2/3

Weight3.24%

1M Return0.89%

Diluted earnings per share (YoY growth rate %)

Value83.61

Score3/3

Weight20.85%

1M Return6.86%

Cash-MV

Value1.35

Score0/3

Weight-5.95%

1M Return-2.55%

Is FMS fundamentally strong?

FMS scores 5.20/10 on fundamentals and holds a Fair valuation at present. Backed by its 6.51% ROE, 6.07% net margin, 11.38 P/E ratio, 0.78 P/B ratio, and 108.17% earnings growth, these metrics solidify its Netural investment rating.